Yin OQ - Search Results

1

Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.

Feng S, Cleary Y, Parrott N, Hu P, Weber C, Wang Y, Yin OQ, Shi J. Feng S, et al. Among authors: yin oq. Eur J Clin Pharmacol. 2015 May;71(5):617-24. doi: 10.1007/s00228-015-1834-y. Epub 2015 Mar 24. Eur J Clin Pharmacol. 2015. PMID: 25801493

2

Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single- and multiple-dose, open-label pharmacokinetic study in Chinese patients.

Zhou L, Meng F, Yin O, Wang J, Wang Y, Wei Y, Hu P, Shen Z. Zhou L, et al. Clin Ther. 2009 Jul;31(7):1568-75. doi: 10.1016/j.clinthera.2009.07.016. Clin Ther. 2009. PMID: 19695406 Clinical Trial.

3

Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.

Yin OQ, Tomlinson B, Chow AH, Waye MM, Chow MS. Yin OQ, et al. J Clin Pharmacol. 2004 Jun;44(6):582-9. doi: 10.1177/0091270004265702. J Clin Pharmacol. 2004. PMID: 15145965 Clinical Trial.

4

Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.

Lawson EB, Wu JC, Baldwin RM, Ingelman-Sundberg M, Rosenborg S, Yim DS, Yin OQ, Capparelli EV, Ma JD. Lawson EB, et al. Among authors: yin oq. Eur J Clin Pharmacol. 2012 Apr;68(4):407-13. doi: 10.1007/s00228-011-1136-y. Epub 2011 Oct 19. Eur J Clin Pharmacol. 2012. PMID: 22009190 Clinical Trial.

5

Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin.

Yin OQ, Merante D, Truitt K, Miller R. Yin OQ, et al. J Clin Pharmacol. 2016 Feb;56(2):203-12. doi: 10.1002/jcph.584. Epub 2015 Sep 2. J Clin Pharmacol. 2016. PMID: 26138993 Clinical Trial.

6

CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.

Yin OQ, Tomlinson B, Chow MS. Yin OQ, et al. Clin Pharmacol Ther. 2005 Oct;78(4):370-7. doi: 10.1016/j.clpt.2005.06.006. Clin Pharmacol Ther. 2005. PMID: 16198656 Clinical Trial.

7

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.

Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD. Larson RA, et al. Among authors: yin oq. Eur J Clin Pharmacol. 2012 May;68(5):723-33. doi: 10.1007/s00228-011-1200-7. Epub 2011 Dec 30. Eur J Clin Pharmacol. 2012. PMID: 22207416 Free PMC article. Clinical Trial.

8

Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation.

Yin OQ, Tetsuya K, Miller R. Yin OQ, et al. Eur J Clin Pharmacol. 2014 Nov;70(11):1339-51. doi: 10.1007/s00228-014-1736-4. Epub 2014 Aug 29. Eur J Clin Pharmacol. 2014. PMID: 25168620 Clinical Trial.

9

Interindividual and intraindividual variability of the urinary 6beta-Hydroxycortisol/Cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity.

Yin OQ, Shi X, Tomlinson B, Chow MS. Yin OQ, et al. J Clin Pharmacol. 2004 Dec;44(12):1412-7. doi: 10.1177/0091270004269760. J Clin Pharmacol. 2004. PMID: 15545313 Clinical Trial.

10

CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.

Yin OQ, Tomlinson B, Chow MS. Yin OQ, et al. J Clin Pharmacol. 2010 Oct;50(10):1136-41. doi: 10.1177/0091270009359006. Epub 2010 Feb 4. J Clin Pharmacol. 2010. PMID: 20133509

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters